ALS, also known as Motor Neuron Disease (MND), Lou Gehrig’s Disease, and Charcot’s disease, is a progressive neurodegenerative disease which attacks motor neurons in the brain and spinal cord resulting in the wasting away of muscle and loss of movement. There is an estimated 30,000 people in the United States living with ALS at any given time and every 90 minutes, someone is diagnosed with the disease. Approximately ninety percent of all ALS cases are sporadic, meaning there is no known history of the disease in a family. The remaining 10 percent of cases are known as familial ALS.
Oxford Biodynamics PLC (LON:OBD) was spun out from Oxford University in June 2007 with the aim of translating fundamental scientific advances into a commercialised platform technology and a new generation of biomarkers for cancer, ALS and other diseases.